Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. 2025 Supervisory Board Report of Krka, d. d., Novo mesto.pdf2025 Supervisory Board Report of Krka Novo mesto

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 19 / 2026
Date of issue: 2026-04-09
Short name of the issuer
KRKA
Subject
025 Supervisory Board Report of Krka, d. d., Novo mesto
Official market - legal basis
Art. 17 ust. 1 MAR
Unofficial market - legal basis
Contents of the report:
Based on the provisions of the Rules of the Ljubljana Stock Exchange, d. d., Ljubljana and Article 134 of the Market in Financial Instruments Act, Krka, d. d., Novo mesto publishes the 2025 Supervisory Board Report of Krka, d. d., Novo mesto.

The report will be published on the Company's website (www.krka.biz) from 9 April 2026 onwards, for a period of at least 10 years.
Annexes
File Description
2025 Supervisory Board Report of Krka, d. d., Novo mesto.pdf
2025 Supervisory Board Report of Krka, d. d., Novo mesto.pdf		 2025 Supervisory Board Report of Krka Novo mesto

KRKA, TOVARNA ZDRAVIL D.D.
(fullname of the issuer)
KRKA Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
8501 Nove Mesto
(post code) (city)
Smarjeska 6
(street) (number)
+386 7 331 21 11 +386 7 332 15 37
(phone number) (fax)
(e-mail) (web site)
nie dotyczy
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2026-04-09 Jože Colarič President of the Management Board and CEO
20260409_081939_2015414152_2025_Supervisory_Board_Report_of_Krka,_d._d.,_Novo_mesto.pdf

Pobierz